Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment

Rhea-AI Summary

Iridex (Nasdaq: IRIX) announced a newly published computational study in Translational Vision Science & Technology modeling thermal dynamics of transscleral glaucoma lasers.

The Monte Carlo simulations compared continuous-wave TSCPC (CW-TSCPC) and MicroPulse TLT using Iridex Cyclo G6, G-Probe and MicroPulse P3. Results: CW-TSCPC produced a ~2 mm thermal zone with temperatures >100°C for ~2.2 seconds, while MicroPulse TLT produced a smaller 0.6–1.2 mm zone with peak temperatures below 100°C and more uniform heat distribution.

Authors say both techniques lie on a thermal continuum and may serve complementary clinical roles with further optimization.

Positive

• MicroPulse TLT thermal zone of 0.6–1.2 mm
• MicroPulse TLT peak temperatures remained below 100°C
• MicroPulse TLT showed more uniform heat distribution
• Study used advanced Monte Carlo simulations for quantitative comparison

Negative

• CW-TSCPC produced a 2 mm heating zone exceeding 100°C for ~2.2 seconds

News Market Reaction

-1.67%

1 alert

-1.67% News Effect

On the day this news was published, IRIX declined 1.67%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

CW-TSCPC thermal zone: 2 mm-wide zone CW-TSCPC temperature: Exceeding 100°C for 2.2 seconds MicroPulse TLT zone: 0.6–1.2 mm thermal zone +1 more

4 metrics

CW-TSCPC thermal zone 2 mm-wide zone Modeled tissue heating width for CW-TSCPC

CW-TSCPC temperature Exceeding 100°C for 2.2 seconds Modeled peak temperature duration for CW-TSCPC

MicroPulse TLT zone 0.6–1.2 mm thermal zone Modeled tissue heating width for MicroPulse TLT

MicroPulse TLT temperature Below 100°C peak Modeled peak temperature for MicroPulse TLT

Market Reality Check

Price: $1.52 Vol: Volume 33,391 is light vs...

low vol

$1.52 Last Close

Volume Volume 33,391 is light vs 20-day average 106,731 (relative volume 0.31). low

Technical Price 0.9403 is trading below the 200-day MA of 1.1 and 51.03% under its 52-week high.

Peers on Argus

IRIX is up 1.33% while key peers like TRIB (-2.57%), ADGM (-10.1%), PTHL (-7.85%...

IRIX is up 1.33% while key peers like TRIB (-2.57%), ADGM (-10.1%), PTHL (-7.85%), and VVOS (-4.17%) are down, pointing to a stock-specific move rather than a sector-wide trend.

Historical Context

5 past events · Latest: Nov 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 11	Q3 2025 earnings	Positive	+8.2%	Revenue growth, lower opex, and improved adjusted EBITDA outlook.
Oct 28	Earnings schedule	Neutral	+2.0%	Announcement of Q3 2025 results release and conference call logistics.
Sep 09	Nasdaq compliance	Positive	-2.8%	Regained compliance with Nasdaq stockholders’ equity listing rules.
Aug 12	Q2 2025 earnings	Negative	-9.2%	Net loss and margin pressure despite revenue growth and cost cuts.
Jul 29	Earnings schedule	Neutral	-0.7%	Scheduling of Q2 2025 results and related investor call details.

Pattern Detected

Earnings updates have produced larger price swings, with positive Q3 numbers drawing an upside reaction, while prior mixed earnings and even clearly positive listing-compliance news saw weaker or negative moves.

Recent Company History

Over the last six months, IRIDEX has focused on stabilizing operations and communicating financial progress. Q2 and Q3 2025 earnings showed year-over-year revenue growth and cost reductions, though profitability remained a challenge. The company also resolved a prior Nasdaq equity compliance issue, with stockholders’ equity rising to $4.681M. Insider and regulatory filings highlighted new preferred equity and a convertible note supporting liquidity. Against this backdrop, the new glaucoma thermal dynamics study further reinforces the clinical and technological foundation behind its glaucoma laser franchise.

Market Pulse Summary

This announcement highlights a TVST study using Monte Carlo modeling to compare thermal effects of C...

Analysis

This announcement highlights a TVST study using Monte Carlo modeling to compare thermal effects of CW-TSCPC and MicroPulse TLT on the ciliary body, showing smaller and cooler thermal zones for MicroPulse TLT. It reinforces the clinical rationale behind IRIDEX’s glaucoma platform rather than near-term financials. In context of recent Q3 2025 revenue of $12.5M and ongoing net losses, investors may watch for how such data translate into probe and system adoption and future earnings reports.

Key Terms

transscleral cyclophotocoagulation, microPulse TLT, monte carlo, ciliary body, +1 more

5 terms

transscleral cyclophotocoagulation medical

"continuous wave transscleral cyclophotocoagulation (CW-TSCPC) and transscleral laser"

Transscleral cyclophotocoagulation is a minimally invasive eye procedure that uses laser energy applied through the white of the eye to reduce the tissue that produces internal eye fluid, lowering pressure for glaucoma patients. Investors pay attention because the procedure drives demand for specialized lasers, consumables and related services, affects clinical outcomes and reimbursement decisions, and can shift market share between drug, device and surgical treatment options much like a more efficient technology can reshape an industry.

microPulse TLT medical

"transscleral laser therapy using MicroPulse® technology (MicroPulse TLT) with Iridex’s Cyclo"

Micropulse TLT (micropulse transscleral laser therapy) is a medical laser treatment for glaucoma that delivers short, repeated bursts of energy through the white of the eye to lower intraocular pressure while aiming to reduce tissue damage compared with continuous laser methods. For investors, it matters because adoption, regulatory approval, and insurance coverage drive device sales, recurring procedure volumes, and competitive positioning in ophthalmic markets—similar to how a gentler, more efficient tool can replace an older, harsher one in a trade.

monte carlo technical

"Using advanced Monte Carlo computer simulations, the authors modeled how each technique"

A Monte Carlo simulation is a computer-based method that explores thousands of possible outcomes by randomly varying key inputs, like returns, interest rates, or costs, to show a range of likely results. For investors it reveals how uncertain factors can affect portfolio value or investment decisions—think of running many different “what if” scenarios, like rolling dice to see all the ways a plan could succeed or fail, so you can judge risk and potential reward.

ciliary body medical

"analyze heat behavior in the ciliary body during CW-TSCPC and MicroPulse TLT treatments"

A ciliary body is a ring of tissue inside the eye, located behind the colored part (iris), that acts like both a tiny pump and a focusing mechanism: it produces the fluid that keeps the eye pressurized and contains muscles that change the lens shape for focusing. It matters to investors because dysfunction or surgical targets in this structure drive demand for drugs, implants and procedures for conditions like glaucoma and vision correction, affecting regulatory risk and commercial opportunity.

continuous wave technical

"continuous wave transscleral cyclophotocoagulation (CW-TSCPC) and transscleral laser therapy"

A continuous wave is an uninterrupted emission of energy—light, sound, or radio—sent at a steady frequency and strength rather than in short pulses. For investors, knowing a product uses continuous-wave technology matters because it affects how the product performs, what applications it suits (for example steady sensing versus range-specific measurements), and how regulators assess safety and efficacy; think of it as a flashlight left on versus one that blinks in bursts.

AI-generated analysis. Not financial advice.

MOUNTAIN VIEW, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today announced a newly published study in Translational Vision Science & Technology (TVST) examining the thermal dynamics of transscleral laser treatments for glaucoma.¹

Led by Tomas M. Grippo, MD, of the Grippo Glaucoma & Cataract Center (Buenos Aires, Argentina), the study provides the first quantitative computer model comparing the thermal tissue effects of continuous wave transscleral cyclophotocoagulation (CW-TSCPC) and transscleral laser therapy using MicroPulse^® technology (MicroPulse TLT) with Iridex’s Cyclo G6^® Laser, G-Probe^® and MicroPulse P3^® delivery devices.

Using advanced Monte Carlo computer simulations, the authors modeled how each technique heats the ciliary body and quantified temperature peaks, duration, and thermal spread. The modeling revealed that CW TSCPC produced a 2 mm-wide zone of tissue heating with temperatures exceeding 100°C for approximately 2.2 seconds. MicroPulse TLT generated a smaller 0.6-1.2 mm thermal zone and shorter duration peak temperatures, remaining below 100°C. Additionally, MicroPulse TLT showed a more uniform heat distribution than CW-TSCPC.

Dr. Grippo explained, “Our study uses a computational model to analyze heat behavior in the ciliary body during CW-TSCPC and MicroPulse TLT treatments. By linking these findings to the safety, effectiveness, and mechanisms of action described in the literature for both treatments, we can reinterpret existing clinical evidence from a fresh perspective. This approach strengthens our understanding and conceptual framework for these techniques and provides insights that may help refine both laser procedures for improved patient outcomes.”

The authors concluded that both techniques share a thermal continuum, and with further optimization, each may evolve to serve distinct but complementary roles from refractory glaucoma to earlier intervention cases.

“Dr. Grippo’s work underscores Iridex’s commitment to advancing evidence-based innovation in glaucoma care,” said Patrick Mercer, CEO of Iridex Corporation. “By deepening our scientific understanding of how these two transscleral laser approaches interact with ocular tissues, we can continue to improve treatment optimization and safety creating broad clinical opportunities for both CW-TSCPC and MicroPulse TLT in modern glaucoma management.”

The article is available in Translational Vision Science & Technology.

About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse^® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.

Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com

Media Contact
Joan Stauffer
jstauffer@iridex.com

For more information about Iridex technologies, visit www.iridex.com.

Iridex, the Iridex logo, MicroPulse^®, the MicroPulse logo, Cyclo G6, MicroPulse P3^®, and G-Probe^® are registered trademarks of Iridex. ©2025 Iridex Corporation. All rights reserved.

References

1. Grippo TM, LaMarche K, Davreux AM, Stauffer J, Stacey S, Arnold K. Thermal tissue modeling of the ciliary body with continuous wave transscleral cyclophotocoagulation and transscleral laser therapy using micropulse technology. Transl Vis Sci Technol. 2025;14(11):32.

FAQ

What did the Iridex (IRIX) study published Dec 8, 2025 compare?

It compared thermal tissue effects of CW-TSCPC and MicroPulse TLT using Iridex Cyclo G6, G-Probe and MicroPulse P3 via Monte Carlo simulations.

How do thermal peaks differ between CW-TSCPC and MicroPulse TLT in the IRIX study?

CW-TSCPC reached temperatures >100°C for ~2.2 seconds; MicroPulse TLT had shorter peaks and stayed below 100°C.

What are the clinical implications of the IRIX thermal dynamics findings for glaucoma treatment?

Authors state both techniques form a thermal continuum and may serve complementary roles from refractory cases to earlier intervention with further optimization.

Which Iridex devices were modeled in the Dec 8, 2025 study?

The study modeled Iridex Cyclo G6 laser with G-Probe and MicroPulse P3 delivery devices.

Where was the Iridex thermal dynamics study published and who led it?

The study was published in Translational Vision Science & Technology and led by Dr. Tomas M. Grippo.